NORRED EXHIBIT 2344 - Page 1
`Medtronic, Inc., Medtronic Vascular, Inc.,
`& Medtronic Corevalve, LLC
`v. Troy R. Norred, MD
`Case IPR2014-00395
`
`

`
`The Corevalve System was developed to serve the needs of the broadest range of patients with
`severe aortic stenosis. The FDA approved the entire Corevalve platform including the Corevalve
`Evo|ut(TM) 23mm, and the Corevalve 26mm, 29mm and 31mm valves. V\fith the broadest size
`range available, the Corevalve System is suitable for patients with native valves of nearly all sizes.
`lts self-expanding nitinol frame enables physicians to deliver the device to the diseased valve in a
`controlled manner, allowing for accurate placement. All valve sizes are delivered via the smallest
`(18Fr, or 6mm) TAVR delivery system available, making it possible to treat patients with difficult or
`small vasculature.
`
`"The FDA approval of Corevalve System is important for U.S. heart teams as the Corevalve System
`will serve the broadest spectrum of aortic stenosis patients who are unable to undergo surgery,"
`said John Liddicoat, M.D., senior vice president, Medtronic, and president of the Medtronic
`Structural Heart Business. "By leveraging Medtronic's history and expertise in bringing therapies to
`patients, we are supporting heart teams through training and education, imaging and patient
`evaluation programs that exemplify our safe and deliberate approach to patient access."
`
`Since obtaining CE (Conformité Européenne) Mark in 2007, the Corevalve System has been
`supported by Medtronic's deep TAVR expertise obtained through more than 50,000 implants outside
`the U.S.
`
`For the High Risk Study of the Corevalve U.S. Pivotal Trial, which is comparing the Corevalve
`System to traditional open heart surgery, the FDA determined it will conduct a separate review of
`the data.
`
`For more information about the Corevalve System, call 877-526-7890 or go to wvvvv.corevalve.com.
`
`In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the
`broadest range of innovative medical technology for the interventional and surgical treatment of
`cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services
`that deliver clinical and economic value to healthcare consumers and providers around the world.
`
`Multimedia Release
`
`A multimedia version of this release, with links to graphics and additional background information
`can be found at: http://bit.|y/1dhZnYP
`
`ABOUT MEDTRONIC
`
`Medtronic, Inc. (wvvw.medtronic.com), headquartered in Minneapolis, is the global leader in medical
`technology - alleviating pain, restoring health and extending life for millions of people around the
`
`Any fonivard-looking statements are subject to risks and uncertainties such as those
`described in Medtronic's periodic reports on file with the Securities and Exchange
`Commission. Actual results may differ materially from anticipated results.
`
`-end-
`
`[i]As presented at Transcatheter Cardiovascular Therapeutics (TCT 2013 Conference, CORE
`VALVE EXTREME RISK: A Prospective Study of Transcatheter Aortic Valve
`NORRED EXHIBIT 2344 - Page 2
`Replacement with a Se|f—Expanding Transcatheter Heart Valve in Patients with
`Severe Aortic Stenosis
`
`

`
`L Contacts:
`Kathleen Janasz
`Public Relations
`+1-763-526-3637
`
`Jeff Warren
`Investor Re|ations
`+1-763-505-2696
`HL!G#1753586
`
`NORRED EXHIBIT 2344 - Page 3
`
`

`
`NORRED EXHIBIT 2344 - Page 4